Show simple item record

dc.contributor.authorAbujudeh, Hani H.
dc.contributor.authorRolls, Hillary
dc.contributor.authorKaewlai, Rathachai
dc.contributor.authorAgarwal, Sheela
dc.contributor.authorGebreananya, Zelalem A.
dc.contributor.authorSaini, Sanjay
dc.contributor.authorSchaefer, Pamela W.
dc.contributor.authorKay, Jonathan
dc.date2022-08-11T08:10:51.000
dc.date.accessioned2022-08-23T17:22:32Z
dc.date.available2022-08-23T17:22:32Z
dc.date.issued2009-12-01
dc.date.submitted2015-04-17
dc.identifier.citationJ Magn Reson Imaging. 2009 Dec;30(6):1335-40. doi: 10.1002/jmri.21976. <a href="http://dx.doi.org/10.1002/jmri.21976">Link to article on publisher's site</a>
dc.identifier.issn1053-1807 (Linking)
dc.identifier.doi10.1002/jmri.21976
dc.identifier.pmid19937927
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48767
dc.description.abstractFrom May 2007 to January 2008, patients with Stage 3-5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)-enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalence of nephrogenic systemic fibrosis (NSF) in renally impaired patients underwent GBD-enhanced MR examinations. In all, 250 patients (98 men, mean age 72.6 years) were included: 97% of the patients had Stage 3 CKD (estimated GFR 30-59 mL/min/1.73 m(2)); 37% had been exclusively exposed to GBD. The remaining were exposed to GBD and other gadolinium-based contrast agents (GBCAs). The mean dose of GBD was 22 mL (standard deviation [SD], 11.2). Including exposure to other GBCAs, the mean cumulative dose of gadolinium was 61 mL (SD, 62.3). A total of 206 patients (82%) had skin examinations following the last GBD administration (mean duration, 108 days). No evidence of suspected or diagnosed NSF was found. In conclusion, on the basis of a retrospective chart review there was no skin evidence of NSF in predominantly Stage 3 CKD patients who were exposed to GBD at an average follow-up of 108 days, either solely or in combination with other GBCAs. J. Magn. Reson. Imaging 2009;30:1335-1340. (c) 2009 Wiley-Liss, Inc.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19937927&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/jmri.21976
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectComorbidity
dc.subjectContrast Media
dc.subjectFemale
dc.subjectHumans
dc.subjectMagnetic Resonance Imaging
dc.subjectMale
dc.subjectMassachusetts
dc.subjectMeglumine
dc.subjectMiddle Aged
dc.subjectNephrogenic Fibrosing Dermopathy
dc.subjectOrganometallic Compounds
dc.subject*Practice Guidelines as Topic
dc.subjectPrevalence
dc.subjectRenal Insufficiency
dc.subjectRetrospective Studies
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.titleRetrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients
dc.typeJournal Article
dc.source.journaltitleJournal of magnetic resonance imaging : JMRI
dc.source.volume30
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/rheumatology_pubs/93
dc.identifier.contextkey7002917
html.description.abstract<p>From May 2007 to January 2008, patients with Stage 3-5 chronic kidney disease (CKD) undergoing gadobenate dimeglumine (GBD)-enhanced magnetic resonance (MR) examinations were included in the retrospective investigation. The electronic medical records were reviewed to assess the prevalence of nephrogenic systemic fibrosis (NSF) in renally impaired patients underwent GBD-enhanced MR examinations. In all, 250 patients (98 men, mean age 72.6 years) were included: 97% of the patients had Stage 3 CKD (estimated GFR 30-59 mL/min/1.73 m(2)); 37% had been exclusively exposed to GBD. The remaining were exposed to GBD and other gadolinium-based contrast agents (GBCAs). The mean dose of GBD was 22 mL (standard deviation [SD], 11.2). Including exposure to other GBCAs, the mean cumulative dose of gadolinium was 61 mL (SD, 62.3). A total of 206 patients (82%) had skin examinations following the last GBD administration (mean duration, 108 days). No evidence of suspected or diagnosed NSF was found. In conclusion, on the basis of a retrospective chart review there was no skin evidence of NSF in predominantly Stage 3 CKD patients who were exposed to GBD at an average follow-up of 108 days, either solely or in combination with other GBCAs. J. Magn. Reson. Imaging 2009;30:1335-1340. (c) 2009 Wiley-Liss, Inc.</p>
dc.identifier.submissionpathrheumatology_pubs/93
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pages1335-40


This item appears in the following Collection(s)

Show simple item record